1. Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold 
Sharon J. Gardiner, Richard B. Gearry, Evan J. Begg, Mei Zhang, Murray L. Barclay 
Clinical Gastroenterology and Hepatology 
Volume 6, Issue 6, Pages (June 2008)
DOI: /j.cgh
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Metabolism of azathioprine and 6-MP. GMPS, guanosine monophosphate synthetase; HGPRT, hypoxanthine guanine phosphoribosyltransferase; IMPDH, inosine monophosphate dehydrogenase; TG, thioguanine; TGMP, thioguanine monophosphate; TGN, thioguanine nucleotides; TIMP, thionosine monophosphate; TXMP, thioxanthosine monophosphate.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2
(A) Thiopurine dose (as azathioprine equivalents) in TPMT*1/*1 (Δ) and *1/*3 (○) genotypes and in (B) normal (Δ, ≥9.3 IU/mL) phenotypes and intermediate (○, 5–9.2 IU/mL) and presented as mean and 95% CI. †Groups became significantly different (P < .05).
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

4. Figure 3 TPMT activity versus weight-adjusted thiopurine dose.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

5. Figure 4
(A) Actual and (B) dose-adjusted 6-TGN concentrations versus TPMT genotype at month 9. Data are presented as mean and 95% CI. Mean actual and dose-adjusted 6-TGN concentrations were 2-fold (P = .016) and 3-fold higher (P = .0007) in the TPMT*1/*3 versus the *1/*1 genotype, respectively.
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions

6. Figure 5
Dose-adjusted 6-TGN concentrations versus TPMT activity (includes line of best fit plus 95% CI of this line).
Clinical Gastroenterology and Hepatology 2008 6, DOI: ( /j.cgh )
Copyright © 2008 AGA Institute Terms and Conditions